Booster Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$5M
- Investors
-
5
Booster Therapeutics General Information
Description
Operator of a biotech company developing drug modalities to eliminate toxic accumulation. The company targets a cellular system that regulates and maintains cellular homeostasis and reinstates balance within cells, enabling healthcare professionals to prevent and treat diseases of aging.
Contact Information
Website
www.boostertx.comCorporate Office
- Berliner Strasse 80-82
- 13189 Berlin
- Germany
Corporate Office
- Berliner Strasse 80-82
- 13189 Berlin
- Germany
Booster Therapeutics Timeline
Booster Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 13-Nov-2025 | $5M | Completed | Clinical Trials - Phase 1 | ||
| 2. Seed Round | 10-Oct-2024 | Completed | Clinical Trials - Phase 1 | |||
| 1. Seed Round | 27-Aug-2021 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Booster Therapeutics Patents
Booster Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025259603-A1 | Pyrrolidine compounds as proteasome stimulators | Pending | 18-Apr-2024 | ||
| WO-2025219559-A1 | Pyrrolidine compounds as proteasome stimulators | Pending | 18-Apr-2024 | ||
| EP-4147723-A1 | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) | Inactive | 09-Sep-2021 | ||
| EP-4398941-A1 | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) | Pending | 09-Sep-2021 | ||
| US-20250121068-A1 | Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods) | Pending | 09-Sep-2021 | A61K47/545 |
Booster Therapeutics Signals
Booster Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Michael J. Fox Foundation | Limited Partner | |||
| Korify Capital | Venture Capital | Minority | ||
| Novo Holdings | Venture Capital | Minority | ||
| Apollo Health Ventures | Venture Capital | Minority | ||
| Infinitas Capital | Family Office | Minority |
Booster Therapeutics FAQs
-
When was Booster Therapeutics founded?
Booster Therapeutics was founded in 2020.
-
Where is Booster Therapeutics headquartered?
Booster Therapeutics is headquartered in Berlin, Germany.
-
What is the size of Booster Therapeutics?
Booster Therapeutics has 8 total employees.
-
What industry is Booster Therapeutics in?
Booster Therapeutics’s primary industry is Drug Discovery.
-
Is Booster Therapeutics a private or public company?
Booster Therapeutics is a Private company.
-
What is Booster Therapeutics’s current revenue?
The current revenue for Booster Therapeutics is .
-
How much funding has Booster Therapeutics raised over time?
Booster Therapeutics has raised $15M.
-
Who are Booster Therapeutics’s investors?
Michael J. Fox Foundation, Korify Capital, Novo Holdings, Apollo Health Ventures, and Infinitas Capital have invested in Booster Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process